Ended March 31,
2008 2007
(Unaudited)
Revenues $25,995 $13,805
Cost of sales 3,125 7,359
Gross profit 22,870 6,446
Development revenues 61,500 -
Expenses:
Research and development 1,358,057 1,400,590
Marketing, general and administrative 1,072,269 877,376
Depreciation and amortization 45,628 46,447
Total expenses 2,475,954 2,324,413
Loss from operations (2,391,584) (2,317,967)
Interest income 33,946 40,624
Interest expense (933,410) (561)
Net interest (expense) income (899,464) 40,063
Loss before income taxes (3,291,048) (2,277,904)
Income taxes - -
Net loss $(3,291,048) $(2,277,904)
Loss per share - basic and diluted $(0.24) $(0.18)
Weighted average shares outstanding - basic
and diluted 13,854,830 12,919,835
Contact: William Kline Lytham Partners, LLC
Chief Financial Officer Joe Diaz
Nicholas Burke Joe Dorame
VP - Financial Operations Robert Blum
(954) 835-1500 (602) 889-9700
'/>"/>SOURCE Bioheart, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 20082.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients3.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 264.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering5.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.6.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets7.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results8.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain9.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter10.
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer11.
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line